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Lipid-lowering therapy in membranous nephropathy. often extremely difficult [1–3]. Proteinuria is a hallmark
Membranous nephropathy (MN) is a very common cause of of MN, and its magnitude has been shown to be one of
nephrotic syndrome in adults, and lipid abnormalities are, there- the most important prognostic indices [4]. As in otherfore, frequently found in these subjects. Although efficient
subjects with an increase of urinary protein excretion,lipid-lowering therapy is available, almost nothing is known
serum lipid abnormalities are one of the most strikingabout the contribution of hyperlipidemia in the pathogenesis
of progressive renal failure in MN. Studies in an experimental laboratory features of patients with MN. Hypercholester-
animal model of human MN, Heymann nephritis, have shown olemia is triggered at least in part by a reduction of plasma
that lipids play an essential role in the pathogenesis of protein- oncotic pressure, which increases the hepatic synthesis ofuria. Local production of reactive oxygen species after subepi-
apolipoprotein B and cholesterol [5]. Especially in patientsthelial immune complex deposition leads to the formation of
with hypertriglyceridemia, an additional acquired defectlipid peroxidation (LPO) adducts, which ultimately alter the
composition of the glomerular basement membrane. As the in low-density lipoprotein (LDL) receptor-mediated re-
magnitude of urinary protein excretion is associated with the moval has been demonstrated [6]. Hypertriglyceridemia,
long-term prognosis, a normalization of glomerular permselec- on the contrary, is mainly due to an impaired very low-
tive properties has been used as a surrogate parameter for the
density lipoprotein (VLDL) metabolism. As the defectbeneficial effects of treatment. Probucol, a drug with LPO
in triglyceride metabolism is more closely related to theinhibitor potential, is able to reduce urinary protein excretion
in rats with passive Heymann nephritis. In humans with MN, renal albumin clearance than to plasma oncotic pressure,
preliminary data also support this observation. It remains to a major role for the urinary loss of a normally nonfiltered
be determined, however, if this intervention, which does not regulator of lipid metabolism is suspected [7].
interfere with immune complex formation, will reduce the num-
Although hyperlipidemia is common in patients withber of patients reaching end-stage renal failure because of MN.
MN and effective therapy is available [8], the exact clini-In conclusion, lipids may contribute to glomerular injury in
MN, as LPO might be an especially important factor, opening cal significance of lipid abnormalities in these subjects is
the possibility for new therapeutic interventions, thereby avoid- still unclear. In a National Institutes of Health consensus
ing the side-effects of the currently used treatment regimen. conference on the treatment of MN, Austin et al con-
cluded that lipid-lowering therapy is warranted only in
cases of persistent nephrotic syndrome to avert the car-
Membranous nephropathy (MN) is a very common diovascular sequelae of hyperlipidemia [9]. Nonetheless,
cause of the nephrotic syndrome in adults. MN can be besides the possibility of an increased cardiovascular risk,
secondary in association with a variety of other diseases experimental observations in animals with renal disease
such as viral infections or neoplasms; more frequently, suggest that hyperlipidemia may enhance the rate of pro-
however, an “idiopathic” form is diagnosed. In these pa- gression of renal injury, in part by promoting an intra-
tients, treatment options are hitherto limited and mostly glomerular equivalent of atherosclerosis [10]. Addition-
rely on immunosuppressive agents. The variable natural ally, tubulointerstitial disease may also be worsened. It
course of the disease, with spontaneous remission oc- has been reported that HDL particles, which have been
curring in a considerable proportion of subjects, the lack shown in vitro to stimulate endothelin-1 production by
of reliable parameters that could identify patients early human proximal tubular cells in culture, can be filtered
on who are likely to progress to renal insufficiency, and in the nephrotic syndrome because of their small size
the limited efficacy and considerable toxicity of the drugs [11]. In a study by Rayner, Byrne, and van Zyl Smit, 17
used for treatment (mainly steroids, cytotoxic agents, patients with MN were treated with a low-cholesterol
and cyclosporine A) make the decision to initiate therapy diet. Nine subjects additionally received the HMG-CoA
reductase inhibitor simvastatin [12]. In the latter, the
total cholesterol and LDL cholesterol were reduced fromKey words: glomerular injury, lipid abnormalities, progressive renal
failure, proteinuria. 10 and 8 mmol/liter to 5.2 and 3.5 mmol/liter, respec-
tively. After a mean follow-up of 19 months, proteinuria, 1999 by the International Society of Nephrology
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as assessed by the urinary protein/creatinine ratio, de- Mechanism of production of reactive oxygen species
creased from 0.52 to 0.13 g/mmol. Furthermore, the se- The initial step in ROS production is the reduction of
rum albumin concentration increased from 26 to 46 g/liter. free oxygen (O2) to superoxide anion (O·22 ). By oxidizing
Diet alone was not successful in lowering serum lipid NADPH to NADP1, the NADPH oxidoreductase gen-
levels, and urinary protein excretion was completely un- erates the needed electron.
affected. Unfortunately, despite this dramatic improve-
2 O2 1 NADPH → H1 1 2O·22 1 NADP1ment of lipid status and urinary protein excretion, the
loss of glomerular filtration rate, as measured by chro- Superoxide anions can pass through cell membranes
mium-labeled ethylenediaminetetraacetic acid clearance, by anion channels and probably do not have a direct
was similar in both groups. Possible explanations for toxic effect but are the precursors of the toxic reactant
this unsatisfactory outcome as far as excretory kidney hydrogen peroxide generated in a reaction catalyzed by
function is concerned are the relatively short follow-up the superoxide dismutase:
period and the low patient number involved. In contrast,
2 O·22 1 2 H1 → O2 1 H2O2it has never been vigorously tested as to whether a reduc-
tion of proteinuria in MN is indeed an ideal surrogate Hydrogen peroxide, per se, has a weak oxygenation
parameter for renal long-term prognosis. capacity, but by the myeloperoxidase reaction, halide
ions (Cl2, Br2, and I2) can be transformed into hypoha-
lite ions, which then are incorporated into the bacterialTHE SIGNIFICANCE OF LIPID PEROXIDATION
cell wall and lead to bacterial killing:IN THE PATHOGENESIS OF PROTEINURIA IN
MEMBRANOUS NEPHROPATHY X2 1 H2O2 1 H1 → HOX 1 H2O
Data obtained in rats with Heymann nephritis, an ani- Additionally, the hydrogen peroxide/myeloperoxidase
mal model of human MN [13], but also some human system can decarboxylate amino acids and transform
data [14], provide evidence that proteinuria is indeed a them into highly reactive aldehydes, carbon dioxide, and
consequence of subepithelial immune complex forma- ammonia:
tion but that some forms of treatment can actually sepa-
R 2 CHNH2 2 COOH → R 2 CHO 1 CO2 1 NH3rate these two events, leaving the intriguing possibility
of allowing studies in MN to evaluate the impact of these Neale et al demonstrated in passive Heymann nephri-
two basic alterations on the progression of the disease tis a high concentration of flavocytochrome b558 in mem-
separately. Kerjaschki et al have published a series of brane vesicles within and on the outside of the glomeru-
animal experiments focusing on these questions [15–20]. lar epithelial cell (GEC) facing the glomerular basement
Subepithelial immune complex formation in rats can be membrane (GBM) [20]. This observation and the finding
induced by binding of an autoimmune-type antibody to of hydrogen peroxide in vacuoles of the GEC and
the endogenous self-antigen complex megalin-receptor– throughout the GBM make it likely that these cells re-
associated protein. However, immune complex forma- semble phagocytes and have the capacity to generate
tion alone does not cause proteinuria, as glomerular per- ROS. In pHN, apolipoprotein A (apoA) and B100 (apoB)
meability is only disturbed once the complement C5b-9 accumulate in immune deposits and the latter shows,
membrane attack complex (MAC) is formed. Comple- when isolated from glomeruli, fragmentation and alde-
ment activation causes sublytic damage of the glomerular hyde-adduct formation [19]. The decarboxylation of lipo-
epithelial cell, which, in turn, up-regulates the NADPH proteins then leads to their conversion to malondialde-
oxidoreductase enzyme complex containing the flavocy- hyde (MDA) and 4-hydroxynonenal (4-HNE). These
tochrome b558. As in the respiratory burst reaction of highly reactive aldehydic fragments then form Schiff
activated neutrophil granulocytes, NADPH oxidoreduc- bases with the lysine residues of proteins (like the a1-
tase is translocated to the cell surface, leading to the chain of type IV) and can be identified by antibodies
formation of radical oxygen species (ROS). In phago- against MDA-lysine or 4-HNE-lysine. The destabiliza-
cytes, an increase of oxygen consumption after exposure tion of glomerular basement membrane by this reaction
to different stimuli is a well-known phenomenon that might be responsible for the loss of filter function and
was initially thought to be primarily due to an increased lead to proteinuria.
oxygen demand during phagocytosis. However, as the
Pathophysiological and clinical implicationscreation of ROS did not correlate with mitochondrial
function, this explanation turned out to be insufficient. If these mechanisms indeed play a causative role in the
After the detection of hydrogen peroxide (H2O2) in the pathogenesis of proteinuria in rats with passive Heymann
surrounding media of activated phagocytes, the concept nephritis and probably human MN, a drug interfering with
LPO should be able to inhibit both MDA formation andof the “respiratory burst” was formed.
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